Register
Login:
Share:
Email Facebook Twitter

Add Verona Pharma to quick picks

Verona Pharma Share Price (VRP)



Share Price Information for Verona Pharma (VRP)


Share Price: 1.50Bid: 1.40Ask: 1.60Change: 0.00 (0.00%)No Movement on Verona Pharma
Spread: 0.20Spread as %: 14.29%Open: 1.50High: 1.50Low: 1.50Yesterday’s Close: 1.50
InfoCFDs vs Share Trading - Download your Free Guide from London South East Markets
When trading CFDs, Forex, and Spread bets, it is possible to lose more than your initial deposit.


Verona Pharma Plc Ord 0.1P

Verona Pharma is listed in the FTSE AIM All-Share
Verona Pharma is part of the Pharmaceuticals & Biotechnology sector






Share Price SpacerPrice
1.50

Share Price SpacerBid
1.40

Share Price SpacerAsk
1.60

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
133,024

Share Price SpacerOpen
1.50

Share Price SpacerHigh
1.50

Share Price SpacerLow
1.50

Share Price SpacerClose
1.50

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 1,009.92m £15.15m 30,000

52 Week High 4.63 52 Week High Date 3-JAN-2014
52 Week Low 1.05 52 Week Low Date 31-OCT-2014

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
8 111,491 0 -2.027 -0.74 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

27-Nov-14
14:07:09
1.49
2,000
Sell* 
1.40
1.60
29.80
Trade Type:
Ordinary

27-Nov-14
13:42:06
1.405
7,103
Sell* 
1.40
1.60
99.80
Trade Type:
Ordinary

27-Nov-14
12:44:37
1.49
3,000
Sell* 
1.40
1.60
44.70
Trade Type:
Ordinary


*Buys and Sells are calculated on the difference between the trade price and the current mid price. As such, they can occasionally be incorrect.

View more Verona Pharma trades >>

Directors Deals for Verona Pharma (VRP)
Trade DateActionNotifierPriceCurrencyAmountHolding
25-Nov-14Buy
Trade Notifier Information for Verona Pharma
Stuart Bottomly held the position of Non-Executive Director at Verona Pharma at the time of this trade.
 Stuart Bottomly
1.45GBX500,00018750000
30-Jun-14Buy
Trade Notifier Information for Verona Pharma
Stuart Bottomly held the position of Non-Executive Director at Verona Pharma at the time of this trade.
 Stuart Bottomly
1.35GBX277,27318250000
04-Oct-13Placing
Trade Notifier Information for Verona Pharma
Stuart Bottomly held the position of Non-Executive Director at Verona Pharma at the time of this trade.
 Stuart Bottomly
2.2GBX2,272,7270
View more Verona Pharma directors dealings >>

Date/Time
Author
Subject
Share Price
Opinion
Today 08:44
rhodi
Cheer Corbs
1.50
No Opinion

Keep it coming and we are all willing this drug to do well and be commercialised. ATB everyone
Wed 17:12
corbine
survey findings
1.50
No Opinion

"The scale of mortality from COPD in Europe is now equivalent to three Hiroshima bombs per year, and unlike many other lung diseases, it is increasing. And the E.U Govs spend how much on research? cures? treatment? How much is lost per annum in GDP facto? through ill health and permanent early retirement? some are dying in their 40's from this disease. Come on 554 stage 2 better be good :-)
Wed 17:09
corbine
COPD EU Update pt 2
1.50
No Opinion

To help raise awareness of the problem within the general public, ECC have produced educational videos which can be viewed on their website (http://www.copdcoalition.eu/) and cover topics such as how to treat COPD and why research into COPD is needed. http://www.medicalnewstoday.com/releases/285743.php?tw imo jmo dypR etc Corbs. Worth a read to understand the scale of the COPD problems/issues and market need for intervention drugs and best practices?
Wed 17:07
corbine
COPD E.U. update
1.50
No Opinion

Results from a new survey looking at the burden of chronic obstructive pulmonary disease (COPD) across 11 European countries have highlighted continued low public awareness of COPD,1 despite the condition causing more than 55 times as many deaths as MRSA (methicillin-resistant staphylococcus aureus).2,3 COPD is a life-threatening lung disease in which the airways are restricted, making it difficult to breathe. It affects up to one in ten adults of the European population and 64 million people die of COPD in the world, every year2. This new survey, conducted among member organisations of the European COPD Coalition (ECC), shows that general public awareness of COPD is low, and few countries have prioritised reducing the burden of a condition that is now the only cause of death whose incidence worldwide is rising. Catherine Hartmann, secretary general of the European COPD Coalition commented on the survey findings: "The scale of mortality from COPD in Europe is now equivalent to three Hiroshima bombs per year, and unlike many other lung diseases, it is increasing. Yet the results of this survey show that very few healthcare systems are addressing the problem adequately. It is the responsibility of health policy makers to provide the right framework of care to improve the health, quality of life and wellbeing of people with COPD; we urge them to give this condition the attention it deserves, to avoid the devastating COPD timebomb we are currently facing." The cost of outpatient care, in-patient care and medical treatment for COPD amounts to over ?10 billion each year. Without intervention, the total number of deaths from COPD is projected to increase by more than 30 per cent in the next decade.2 COPD is the fifth biggest cause of deaths worldwide, and kills 250 people every hour. The ECC member survey 2014 was conducted among 11 European COPD Coalition affiliated respiratory country organisations. They were asked of their knowledge of the overall burden of COPD in their country, if they thought COPD was regarded as a significant health issue in their countries, and if they knew what level of attention COPD receives among public health and policy makers. Key survey findings include: In no country were people thought to be more aware of COPD than other lung diseases like asthma Only 6.25 per cent of organisations surveyed felt that their country had a good public health strategy in place to reduce COPD More than 3 out of 5 (62.5 per cent) of the lung organisations surveyed felt their own healthcare system regarded COPD as low/very low priority Almost 9 out of 10 organisations surveyed (87.5 per cent) felt that COPD received too little attention in their countries Four out of five organisations (80 per cent) surveyed believed that their countries would benefit from greater public awareness of the problem tbc
Wed 14:07
mathsprof
RE: Hello Mathsprof
1.53
No Opinion

Thanks, Buddyhell. I was a bit confused but now the post makes good sense. I hope we can hold at the 1.5-1.6p level now, rather than drift back like last time. Its only a few buyers supporting the SP, and they will probably stop buying soon.
Wed 12:53
corbine
this is good
1.53
No Opinion

a few more directors buys could help confidence=money where mouth is and create some interest here. good to see directos having confidence in their product. :-)

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Verona Pharma (VRP) >>
Please Login or Register to post messages

Share Trading BrochureRequest your Free brochures on share dealing, spread betting and CFDs




Sign up for Live Prices


CD02WL.001.081313
Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.